Eledon Pharmaceuticals, Inc (ELDN) - Long-Term Debt to Capital Coefficient
Eledon Pharmaceuticals (ELDN) business risks are tied to the trial results of anti-rejection therapies and pressure from traditional treatment methods. The price action on GURU.Markets for the separate_debt_long_eq metric stands at 0.00. US laboratories developing immunological innovations ensure the company's stability. Independence from global economic fluctuations and steady demand for biotechnology turn the asset into a high-quality defensive tool.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_ELDN_-_Eledon-Pharmaceuticals_-_Long-Term-Debt-to-Capital "ELDN: Eledon Pharmaceuticals, Inc. Long-Term Debt to Capital 07/04/2022 - 10/31/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Eledon Pharmaceuticals (ELDN)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Eledon Pharmaceuticals|ELDN - Long-Term Debt to Capital|Short-Term Debt to Capital eledon.com|ELDN - Company Total Debt|Debt to Net Assets Ratio Eledon Pharmaceuticals, Inc.|ELDN - Company Long-Term Debts|Short-Term Debt Volume Eledon Pharmaceuticals|Quick Liquidity Indicator eledon.com
- net income and valuation ratios data:
General company analysis:Eledon Pharmaceuticals Inc. - ELDN
Strong liquidity and the management competencies of Eledon Pharmaceuticals (ELDN) in immunological biotech drive the stable dynamics of the long-term debt-to-equity ratio. This ratio, calculated as long-term liabilities divided by total equity, measures the company's financial leverage; its low values confirm independent development and risk minimization through effective management of borrowed capital.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient KNSA (Kiniksa Pharmaceuticals, Ltd.)|Grifols Group (GRFS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Adaptive Biotechnologies Inc.|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com|Long-Term Debt to Equity Ratio BCRX (BioCryst Pharmaceuticals)|VERA (Vera Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital DNTH (Dianthus Pharma)|Ratio of Long-Term Indebtedness to Capital Pharvaris Pharma (PHVS)|ABCL - Long-Term Debt to Equity|tourmalinebio.com (TRML) - Long-Term Debt to Equity Ratio|Precigen (PGEN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|Long-Term Debt to Equity Ratio NKTR|Long-Term Debt to Capital Upstream Pharma|Long-Term Debt to Equity Zenas Biopharma Inc (ZBIO)|immunome.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital GOSS (Gossamer Bio)|KalVista Pharma (KALV) - Long-Term Liabilities to Capital|Septerna Corp - Long-Term Debt to Capital|Long-Term Liabilities to Capital Pieris Corp|Savara Inc. (SVRA) - Long-Term Debt to Equity|RIGL (rigel.com) - Long-Term Debt to Equity|ANAB (AnaptysBio) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Astria Therapeutics Inc ATXS|Long-Term Debt to Capital ENGN|rapt.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Equity Aerovate Therapeutics JBIO|aclaristx.com (ACRS) - Long-Term Liabilities to Capital|KYTX - Long-Term Debt to Equity|TLSA (Tiziana Life Sciences Ltd.) - Long-Term Debt to Capital Ratio|CABA (Cabaletta Bio, Inc) - Long-Term Debt to Equity Ratio|Ventyx Biosciences, Inc - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Theratechnologies Inc.|avalotx.com - Long-Term Liabilities to Equity|Long-Term Debt to Capital AGEN|CLYM (Climb Bio Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ZURA (Zura Bio Limited)|Long-Term Debt to Capital aTyr Pharmaceuticals ATYR|ADAG - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient IMA (ImageneBio Inc)|shattucklabs.com (STTK) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Equillium|CNTB (Connect Biopharma Holdings) - Long-Term Debt to Capital|Long-Term Debt to Capital Immunic Inc|Long-Term Debt to Capital ATRA|Long-Term Debt to Equity Ratio inflarx.de IFRX|Long-Term Debt to Capital XFOR (X4 Pharmaceuticals, Inc.)|Adicet Bio Inc. (ACET) - Long-Term Liabilities to Capital|CELU: Long-Term Debt to Equity Ratio|INMB - Long-Term Debt to Capital|BRNS (Barinthus Biotherapeutics) - Long-Term Debt to Equity Ratio|KZR: Long-Term Loans to Capital Ratio|SABS (SAB Biotherapeutics, Inc.) - Long-Term Debt to Capital|Akari Therapeutics PLC (AKTX) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital ENLV|Long-Term Debt to Equity Ratio q32bio.com QTTB|Long-Term Debt to Capital GOVX (GeoVax Labs, Inc.)|Long-Term Debt to Capital edesabiotech.com EDSA|IBIO - Long-Term Debt to Equity|CARM: Long-Term Debt to Equity|XTL Biopharmaceuticals, Ltd. (XTLB) - Long-Term Debt to Equity|BOLT - Ratio of Long-Term Indebtedness to Capital|HCWB (HCW Biologics, Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Aptevo APVO|Long-Term Debt to Equity AIM ImmunoTech (AIM)|Long-Term Debt to Equity ADTX (aditxt.com)|Long-Term Debt to Capital GRI (GRI Bio Corp)|XRTX: Long-Term Debt to Capital Ratio|HIND - Long-Term Debt to Equity|REVB (revbiosciences.com) - Long-Term Debt to Capital Ratio|Indaptus Therapeutics, Inc. (INDP) - Long-Term Debt to Equity|Long-Term Liabilities to Equity SCNI (Scinai Immunotherapeutics Ltd)|CALI (CalciMedica Inc) - Long-Term Debt to Capital|AFMD: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ALLK|Long-Term Debt to Capital hookipapharma.com (HOOK)|Long-Term Debt to Equity IGM Biosciences IGMS|Long-Term Debt to Capital Coefficient ITOS|OCEA - Long-Term Debt to Equity|TC BioPharm Ltd (TCBP) - Long-Term Debt to Equity Ratio|THRD: Long-Term Debt to Capital